Soleno Therapeutics Quarterly Income Statements Chart
Quarterly
|
Annual
Soleno Therapeutics Quarterly Income Statements Table
Quarterly
|
Annual
| Unit: USD | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 | 2021-09-30 | 2021-06-30 | 2021-03-31 | 2020-12-31 | 2020-09-30 | 2020-06-30 | 2020-03-31 | 2019-12-31 | 2019-09-30 | 2019-06-30 | 2019-03-31 | 2018-12-31 | 2018-09-30 | 2018-06-30 | 2018-03-31 | 2017-12-31 | 2017-09-30 | 2017-06-30 | 2017-03-31 | 2016-12-31 | 2016-09-30 | 2016-06-30 | 2016-03-31 | 2015-12-31 | 2015-09-30 | 2015-06-30 | 2015-03-31 | 2014-12-31 | 2014-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| revenue | 22,000 | |||||||||||||||||||||||||||||||||||||||||||
| yoy | ||||||||||||||||||||||||||||||||||||||||||||
| qoq | ||||||||||||||||||||||||||||||||||||||||||||
| product revenue | 32,657,000 | 1,000 | 265,000 | 283,788 | 329,000 | 391,000 | 447,000 | 241,555 | 92,000 | 32,000 | ||||||||||||||||||||||||||||||||||
| total revenue | 32,657,000 | 283,788 | 329,000 | 241,472 | 247,000 | 97,000 | ||||||||||||||||||||||||||||||||||||||
| operating expenses | ||||||||||||||||||||||||||||||||||||||||||||
| cost of goods sold | 696,000 | |||||||||||||||||||||||||||||||||||||||||||
| research and development | 9,147,000 | 13,517,000 | 21,486,000 | 30,138,000 | 12,342,000 | 14,602,000 | 8,689,000 | 6,043,000 | 5,141,000 | 5,316,000 | 3,810,000 | 3,771,000 | 3,696,000 | 3,988,000 | 3,734,000 | 4,968,000 | 5,587,000 | 7,164,000 | 5,566,000 | 4,827,000 | 6,103,000 | 6,695,000 | 5,272,000 | 4,490,000 | 3,745,000 | 2,760,000 | 2,192,000 | 2,092,000 | 1,714,000 | 1,180,000 | 1,022,742 | 982,000 | 974,000 | 994,000 | 953,803 | 1,131,000 | 1,327,000 | 1,772,000 | 1,284,244 | 1,193,000 | 1,181,000 | 878,000 | 609,216 | 717,000 |
| selling, general and administrative | 28,238,000 | 29,259,000 | ||||||||||||||||||||||||||||||||||||||||||
| change in fair value of contingent consideration | 1,101,000 | 2,967,000 | 327,000 | 877,000 | 1,637,000 | 401,000 | 1,081,000 | 1,021,000 | 313,000 | 299,000 | -602,000 | 132,000 | 616,000 | -858,000 | -3,329,000 | 551,000 | 3,034,000 | -987,000 | 140,000 | 774,000 | 2,842,000 | 584,000 | -128,000 | 28,000 | 183,000 | 206,000 | -22,000 | 228,000 | -67,000 | 428,000 | ||||||||||||||
| total operating expenses | 39,182,000 | 45,743,000 | 59,116,000 | 80,212,000 | 24,868,000 | 23,475,000 | 13,910,000 | 10,382,000 | 8,623,000 | 8,469,000 | 5,610,000 | 6,235,000 | 6,779,000 | 5,773,000 | 3,001,000 | 8,286,000 | 11,085,000 | 9,156,000 | 7,957,000 | 7,857,000 | 11,193,000 | 9,282,000 | 6,752,000 | 6,133,000 | 5,623,000 | 4,978,000 | 3,535,000 | 3,878,000 | 3,413,000 | 3,475,000 | ||||||||||||||
| operating income | -6,525,000 | -45,743,000 | -59,116,000 | -80,212,000 | -24,868,000 | -23,475,000 | -13,910,000 | -10,382,000 | -8,623,000 | -8,469,000 | -5,610,000 | -6,235,000 | -6,779,000 | -5,773,000 | -3,001,000 | -8,286,000 | -11,085,000 | -9,156,000 | -7,957,000 | -7,857,000 | -11,193,000 | -9,282,000 | -6,752,000 | -6,133,000 | -5,623,000 | -4,978,000 | -3,535,000 | -3,878,000 | -3,413,000 | -3,475,000 | -5,199,315 | -2,689,000 | -3,210,000 | -2,210,000 | -2,956,115 | -2,941,000 | -3,450,000 | -4,263,000 | -3,506,746 | -3,183,000 | -3,044,000 | -2,426,000 | -1,845,729 | -1,323,000 |
| yoy | -73.76% | 94.86% | 324.99% | 672.61% | 188.39% | 177.19% | 147.95% | 66.51% | 27.20% | 46.70% | 86.94% | -24.75% | -38.85% | -36.95% | -62.28% | 5.46% | -0.96% | -1.36% | 17.85% | 28.11% | 99.06% | 86.46% | 91.00% | 58.15% | 64.75% | 43.25% | -32.01% | 44.22% | 6.32% | 57.24% | 75.88% | -8.57% | -6.96% | -48.16% | -15.70% | -7.60% | 13.34% | 75.72% | 89.99% | 140.59% | ||||
| qoq | -85.74% | -22.62% | -26.30% | 222.55% | 5.93% | 68.76% | 33.98% | 20.40% | 1.82% | 50.96% | -10.02% | -8.02% | 17.43% | 92.37% | -63.78% | -25.25% | 21.07% | 15.07% | 1.27% | -29.80% | 20.59% | 37.47% | 10.09% | 9.07% | 12.96% | 40.82% | -8.84% | 13.62% | -1.78% | -33.16% | 93.35% | -16.23% | 45.25% | -25.24% | 0.51% | -14.75% | -19.07% | 21.57% | 10.17% | 4.57% | 25.47% | 31.44% | 39.51% | |
| operating margin % | -11027.27% | |||||||||||||||||||||||||||||||||||||||||||
| other income | 11,886 | -602,000 | 20,233 | -9,000 | -16,000 | -2,000 | -565 | -183,000 | 4,925,000 | -3,690,475 | -318,000 | |||||||||||||||||||||||||||||||||
| interest income | 3,193,000 | 3,331,000 | 3,365,000 | 3,596,000 | 3,014,000 | 2,077,000 | 2,144,000 | 174,000 | 147,000 | 113,000 | 125,000 | 101,000 | 52,000 | 22,000 | 34,000 | 34,000 | 41,000 | 1,000 | 3,250 | 1,000 | 1,000 | 11,000 | 33,250 | 29,000 | 47,000 | 57,000 | 1,750 | 4,000 | 3,000 | 1,000 | 85 | |||||||||||||
| interest expense | -1,376,000 | -1,361,000 | -250 | |||||||||||||||||||||||||||||||||||||||||
| total other income | 1,817,000 | 1,970,000 | 3,134,000 | 3,596,000 | 3,014,000 | 2,077,000 | 2,614,000 | -479,000 | 148,000 | 113,000 | 124,000 | 103,000 | 54,000 | 49,000 | 173,000 | 146,000 | 97,000 | 202,000 | 5,105,000 | -688,000 | 3,809,000 | 3,424,000 | -7,873,000 | 7,022,000 | -4,385,000 | -2,052,000 | 3,928,000 | 1,569,000 | -3,801,000 | 234,000 | ||||||||||||||
| net income | -4,708,000 | -43,773,000 | -55,982,000 | -76,616,000 | -21,854,000 | -21,398,000 | -11,296,000 | -10,861,000 | -8,475,000 | -8,356,000 | -5,486,000 | -6,132,000 | -6,725,000 | -5,724,000 | -2,828,000 | -8,140,000 | -10,988,000 | -8,954,000 | -2,852,000 | -8,545,000 | -7,384,000 | -5,858,000 | -14,625,000 | 889,000 | -10,008,000 | -7,030,000 | 263,000 | -2,736,000 | -7,637,000 | -3,755,000 | -5,025,425 | -3,786,000 | -3,966,000 | -2,887,000 | -2,613,214 | -2,750,000 | -3,513,000 | -3,189,000 | -2,844,546 | -3,293,000 | 1,881,000 | -11,651,000 | ||
| yoy | -78.46% | 104.57% | 395.59% | 605.42% | 157.86% | 156.08% | 105.91% | 77.12% | 26.02% | 45.98% | 93.99% | -24.67% | -38.80% | -36.07% | -0.84% | -4.74% | 48.81% | 52.85% | -80.50% | -1061.19% | -26.22% | -16.67% | -5660.84% | -132.49% | 31.05% | 87.22% | -105.23% | -27.73% | 92.56% | 30.07% | 92.31% | 37.67% | 12.89% | -9.47% | -8.13% | -16.49% | -286.76% | -72.63% | ||||||
| qoq | -89.24% | -21.81% | -26.93% | 250.58% | 2.13% | 89.43% | 4.01% | 28.15% | 1.42% | 52.31% | -10.53% | -8.82% | 17.49% | 102.40% | -65.26% | -25.92% | 22.72% | 213.96% | -66.62% | 15.72% | 26.05% | -59.95% | -1745.11% | -108.88% | 42.36% | -2773.00% | -109.61% | -64.17% | 103.38% | -25.28% | 32.74% | -4.54% | 37.37% | 10.48% | -4.97% | -21.72% | 10.16% | 12.11% | -13.62% | -275.07% | -116.14% | |||
| net income margin % | -52959.09% | |||||||||||||||||||||||||||||||||||||||||||
| other comprehensive income | ||||||||||||||||||||||||||||||||||||||||||||
| net unrealized loss on marketable securities | -153,000 | -139,000 | -46,000 | -105,000 | ||||||||||||||||||||||||||||||||||||||||
| foreign currency translation adjustment | 12,000 | 4,000 | -750 | -1,000 | -1,000 | -1,000 | -250 | -1,000 | -16,000 | 16,000 | -500 | -1,000 | 1,000 | -2,000 | ||||||||||||||||||||||||||||||
| total comprehensive loss | -4,849,000 | -43,908,000 | -56,516,000 | -75,568,000 | -21,901,000 | -21,504,000 | -6,923,250 | -10,862,000 | -8,491,000 | -8,340,000 | -4,645,750 | -6,133,000 | -6,724,000 | -5,726,000 | ||||||||||||||||||||||||||||||
| net income per common share, basic and diluted | -90 | -950 | -1,300 | -1,830 | -570 | -590 | 290 | -950 | -810 | -880 | -270 | -760 | -60 | -70 | -87.5 | -100 | -140 | -110 | -160 | -130 | -310 | -220 | 30 | -130 | -380 | -190 | 1,188.25 | -350 | -70 | -110 | ||||||||||||||
| weighted-average common shares outstanding used to calculate basic and diluted net income per common share | 50,483,281,000 | 46,178,793,000 | 40,175,926,000 | 41,879,025,000 | 38,631,565,000 | 36,208,371,000 | 16,492,132,000 | 11,436,748,000 | 10,423,598,000 | 9,447,350,000 | 8,397,088,000 | 8,093,033,000 | 120,088,816,000 | 80,020,677,000 | 79,770,334,000 | 79,791,075,000 | 79,747,506,000 | 79,694,781,000 | 62,620,227,000 | 46,236,209,000 | 44,679,858,000 | 34,142,478,000 | 31,776,951,000 | 31,756,120,000 | 20,975,479,000 | 21,432,482,000 | 20,345,437,000 | 19,530,311,000 | 8,977,795 | 10,766,608,000 | 53,060,868,000 | 26,853,433,000 | 15,507,484 | 15,761,530 | 14,796,119,000 | 9,425,880 | 10,040,079,000 | 6,965,483,000 | 1,270,033 | 535,685,000 | ||||
| general and administrative | 37,303,000 | 49,197,000 | 10,889,000 | 8,472,000 | 4,140,000 | 3,318,000 | 3,169,000 | 2,854,000 | 2,402,000 | 2,332,000 | 2,467,000 | 2,643,000 | 2,596,000 | 2,767,000 | 2,464,000 | 2,979,000 | 2,251,000 | 2,256,000 | 2,248,000 | 2,003,000 | 1,608,000 | 1,615,000 | 1,695,000 | 2,012,000 | 1,365,000 | 1,558,000 | 1,766,000 | 1,867,000 | 1,684,650 | 1,707,000 | 2,195,000 | 1,158,000 | 1,890,203 | 1,398,000 | 1,509,000 | 1,939,000 | 1,708,821 | 1,714,000 | 1,432,000 | 1,292,000 | 1,080,154 | 522,000 | ||
| change in fair value of warrants liabilities | -163,000 | -653,000 | 1,000 | 7,750 | 2,000 | 2,000 | 27,000 | 139,000 | 112,000 | 56,000 | 201,000 | 5,105,000 | -689,000 | 3,808,000 | 3,413,000 | -7,894,000 | 7,116,000 | -4,267,000 | -1,919,000 | 2,071,000 | 1,543,000 | -3,834,000 | 212,000 | 344,117 | 200,000 | -47,000 | 1,170,000 | 661,140 | 73,000 | 4,925,000 | -6,174,000 | |||||||||||||
| net unrealized gain on marketable securities | -537,000 | 1,049,000 | ||||||||||||||||||||||||||||||||||||||||||
| other comprehensive loss | ||||||||||||||||||||||||||||||||||||||||||||
| income from minority interest investment | -123,000 | -165,000 | -190,000 | |||||||||||||||||||||||||||||||||||||||||
| net income per common share: | ||||||||||||||||||||||||||||||||||||||||||||
| basic | -95 | -110 | -127.5 | 30 | -230 | 250 | ||||||||||||||||||||||||||||||||||||||
| diluted | -95 | -110 | -132.5 | -190 | -230 | 250 | ||||||||||||||||||||||||||||||||||||||
| weighted-average common shares outstanding used in per-share calculation: | ||||||||||||||||||||||||||||||||||||||||||||
| basic | 79,583,254,000 | 31,793,292,000 | 15,528,922,000 | 7,517,794,000 | ||||||||||||||||||||||||||||||||||||||||
| diluted | 79,583,254,000 | 32,443,647,000 | 15,528,922,000 | 7,630,644,000 | ||||||||||||||||||||||||||||||||||||||||
| cease-use income | 3,000 | 3,000 | ||||||||||||||||||||||||||||||||||||||||||
| income from continuing operations | -14,625,000 | 889,000 | -10,008,000 | -7,030,000 | 393,000 | -2,309,000 | -7,214,000 | -3,241,000 | -4,480,850 | -2,551,000 | ||||||||||||||||||||||||||||||||||
| income from discontinued operations | -423,000 | -514,000 | ||||||||||||||||||||||||||||||||||||||||||
| income per common share from continuing operations: | ||||||||||||||||||||||||||||||||||||||||||||
| basic | -127.5 | 30 | ||||||||||||||||||||||||||||||||||||||||||
| diluted | -132.5 | -190 | ||||||||||||||||||||||||||||||||||||||||||
| loss per common share from discontinued operations: | ||||||||||||||||||||||||||||||||||||||||||||
| basic | ||||||||||||||||||||||||||||||||||||||||||||
| diluted | ||||||||||||||||||||||||||||||||||||||||||||
| loss per common share from continuing operations, basic and diluted | -310 | -220 | 40 | -110 | -360 | -170 | 848.65 | -240 | ||||||||||||||||||||||||||||||||||||
| loss per common share from discontinued operations, basic and diluted | -20 | -20 | -20 | |||||||||||||||||||||||||||||||||||||||||
| sales and marketing | -269 | 114,000 | 173,591 | 342,000 | 577,000 | 538,000 | 498,470 | 467,000 | 506,000 | 260,000 | 156,359 | 84,000 | ||||||||||||||||||||||||||||||||
| interest and other income | -137,000 | 26,000 | 30,000 | 19,000 | -155,250 | 138,000 | -29,000 | -677,000 | 300,500 | 191,000 | -63,000 | 1,074,000 | ||||||||||||||||||||||||||||||||
| loss on sale of assets | -52,000 | -208,000 | ||||||||||||||||||||||||||||||||||||||||||
| total | -130,000 | -427,000 | -762,250 | -1,235,000 | ||||||||||||||||||||||||||||||||||||||||
| total expenses | 1,743,000 | 2,689,000 | 3,169,000 | 2,266,000 | 3,017,597 | 2,871,000 | 3,413,000 | 4,249,000 | 3,491,535 | 3,374,000 | 3,119,000 | 2,430,000 | 1,845,729 | 1,323,000 | ||||||||||||||||||||||||||||||
| change in fair value of warrants liabilities income | -7,250 | 130,000 | -32,000 | -69,000 | ||||||||||||||||||||||||||||||||||||||||
| cease-use expense | 750 | 4,000 | -7,000 | 251 | -94,000 | |||||||||||||||||||||||||||||||||||||||
| income from discontinued operations: | ||||||||||||||||||||||||||||||||||||||||||||
| operating | -80 | -90 | ||||||||||||||||||||||||||||||||||||||||||
| cost of product revenue | 42,000 | 209,000 | 321,750 | 399,000 | 428,000 | 461,000 | 24,000 | 56,000 | 22,000 | |||||||||||||||||||||||||||||||||||
| gross loss | -41,000 | |||||||||||||||||||||||||||||||||||||||||||
| expenses | ||||||||||||||||||||||||||||||||||||||||||||
| net income from continuing operations | -3,239,000 | |||||||||||||||||||||||||||||||||||||||||||
| net income from discontinued operations | -727,000 | |||||||||||||||||||||||||||||||||||||||||||
| net income per common share from continuing operations, basic and diluted | -60 | |||||||||||||||||||||||||||||||||||||||||||
| net income per common share from discontinued operations, basic and diluted | -10 | |||||||||||||||||||||||||||||||||||||||||||
| gross profit | 56,000 | 61,482 | -70,000 | -37,000 | -14,000 | -15,211 | 191,000 | 75,000 | 4,000 | |||||||||||||||||||||||||||||||||||
| yoy | -500.00% | -504.19% | -136.65% | -149.33% | -450.00% | |||||||||||||||||||||||||||||||||||||||
| qoq | -8.92% | -187.83% | 89.19% | 164.29% | -7.96% | -107.96% | 154.67% | 1775.00% | ||||||||||||||||||||||||||||||||||||
| gross margin % | 18.18% | |||||||||||||||||||||||||||||||||||||||||||
| government grant revenue | -83 | 155,000 | 65,000 | |||||||||||||||||||||||||||||||||||||||||
| inducement charge for series c warrants | 625 | -3,050,000 | ||||||||||||||||||||||||||||||||||||||||||
| loss on extinguishment of convertible preferred stock | 7,302,172 | -3,651,000 | ||||||||||||||||||||||||||||||||||||||||||
| net income attributable to common stockholders | -3,275,750 | -6,401,000 | ||||||||||||||||||||||||||||||||||||||||||
| net income per share | -0.213 | -0.41 | ||||||||||||||||||||||||||||||||||||||||||
| weighted-average common shares outstanding used to calculate net income per common share: | ||||||||||||||||||||||||||||||||||||||||||||
| basic | 79,583,254,000 | 31,793,292,000 | 15,528,922,000 | 7,517,794,000 | ||||||||||||||||||||||||||||||||||||||||
| diluted | 79,583,254,000 | 32,443,647,000 | 15,528,922,000 | 7,630,644,000 | ||||||||||||||||||||||||||||||||||||||||
| basic and diluted net income per common share | -220 | 1,598.31 | -330 | -1,670 | 11,229.08 | -4,470 | ||||||||||||||||||||||||||||||||||||||
| cost of revenue | 18,000 | |||||||||||||||||||||||||||||||||||||||||||
| interest | -1,000 | -452,750 | -752,000 | |||||||||||||||||||||||||||||||||||||||||
| net income and comprehensive loss | -1,504,750 | -2,393,000 |
We provide you with 20 years income statements for Soleno Therapeutics stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as earnings, sales and marketing expenses, research and development costs, profits, and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Soleno Therapeutics stock. Explore the full financial landscape of Soleno Therapeutics stock with our expertly curated income statements.
The information provided in this report about Soleno Therapeutics stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.